GlassScriptPhysician profile
Khalid Yaqoob
NPI 1285686428
$3,549.08
in general payments reported to CMS, 2019-2025
27 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $360 · 2021: $445 · 2022: $371 · 2023: $985 · 2024: $692 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $555.63 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $499.37 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $428.95 | 2023-2024 | Assure Wcd |
| Medicomp INC | $278.78 | 2023 | Telepatch Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $249.03 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $243.87 | 2019-2025 | |
| Medtronic, INC. | $192.59 | 2021-2023 | Micra, Venaseal, Reveal Linq |
| Abiomed | $179.33 | 2023-2024 | Impella |
| Medtronic Vascular, INC. | $146.53 | 2019-2020 | |
| Boston Scientific Corporation | $136.22 | 2019-2022 | |
| Amgen INC. | $135.82 | 2019-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $84.29 | 2022-2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.97 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $52.36 | 2021-2022 | |
| Chiesi USA, INC. | $35.68 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $31.93 | 2025 | Barostim Neo System |
| Abbott Laboratories | $30.91 | 2021-2023 | Confirm Rx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.60 | 2019-2021 | |
| Esperion Therapeutics, INC. | $26.24 | 2020 | |
| Terumo Medical Corporation | $26.09 | 2019 | |
| Ge Healthcare | $22.00 | 2025 | |
| Heartflow, INC. | $20.83 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $19.45 | 2023 | |
| Amarin Pharma, INC. | $18.54 | 2020 | |
| Merck Sharp & Dohme LLC | $18.48 | 2021 | |
| Angiodynamics, INC. | $15.43 | 2019 | |
| Genzyme Corporation | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Yaqoob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.